What Can you Expect at the Premium Extrahepatic Delivery Summit 2026?
The 5th Extrahepatic Lipid-Based Nanoparticles Delivery Summit 2026 is the only industry-led event exclusively focussed on uncovering novel lipid-based delivery vehicle design and formulation for precise, selective delivery beyond the liver.
Across focused sessions on novel targeting strategies, advanced LNP formulations, innovative nanoparticle architectures, and robust screening approaches, this meeting is your one-stop-shop to stay at the cutting-edge of extrahepatic delivery. Join experts in delivery, formulation, discovery and R&D to tackle extrahepatic barriers and define the ideal delivery vehicle needed to unlock the full potential of mRNA, RNA, DNA, cell, and gene therapies.
At the 2026 event, expect immersive workshops, data-driven presentations, deep-dive discussions, and dedicated networking opportunities to equip you with the insights, data, and strategies needed to transform delivery pipelines, design selective lipid-based nanoparticles, and advance more potent drug products towards the clinic.
Dive deep into targeted LNP analytics and processes to achieve high quality, reliable large manufacturing for advancing effective and commercially viable delivery systems with insights from Novo Nordisk and AstraZeneca
Explore emerging nanoparticle vehicles leveraging novel polymers and peptides to achieve improved delivery efficiency and reduced immunogenicity with insights from AANASTRA, Novartis, and Feldan Therapeutics
Delve into data-driven case studies uncovering innovative delivery solutions with improved organ tropisms for targeting immune cells, tumors, muscle, and adipose tissues with insights from Novartis, Canary Cure Therapeutics, and Corner Therapeutics
What's New for 2026?
New Industry Leading Speakers
8+ brand new companies on the speaker faculty, hear fresh perspectives from Flashpoint Therapeutics, RNA Nanobiotics, Corner Therapeutics, Zipcode Bio, Novartis, and more to explore new screening strategies, targeting approaches, and innovative nanoparticle formulations to achieve precise delivery outside the liver.
Brand New Data Being Presented
Feldan Therapeutics, AbbVie, Canary Cure Therapeutics, GT Biosciences, and many others will be sharing never before seen data during in-depth, technical case studies for advancing safe and selective delivery of RNA, mRNA, gene editing, and cell therapy payloads.
Broader Networking Opportunities
More curated networking sessions, including interactive roundtables, workshop sessions, panel discussions, and speed networking opportunities to enable you to join forces with other non-viral delivery experts and collectively face challenges limiting precise extrahepatic delivery.
Explore the Full Event Guide
- 23+ expert speakers from pioneering biotech and large pharma, including AbbVie, Strand Therapeutics, AstraZeneca, Mote Therapeutics, Corner Therapeutics, Novo Nordisk, Novartis, and more
- Gain in-depth technical insights into achieving precise and selective delivery to muscle, adipose tissue, immune cells, and other extrahepatic targets
- 6 interactive workshops, roundtables and panel discussions to solve challenges in targeted LNP analytics, scalability as well as compare innovative solutions in passive and active targeting
Attending Companies Include
Explore the Agenda
Discover the latest breakthroughs shaping extrahepatic targeting, from novel targeting strategies to innovative non-viral formulations. Gain exclusive insights from industry leaders during data-driven presentations, interactive roundtables, and expert panel discussions.
Partner With Us
Showcase your solutions alongside other leading solution providers to a community dedicated to cutting-edge delivery innovation. Position your brand at the heart of the biopharma deals and partnerships defining RNA, cell, and gene therapy pipelines.
Join Biopharma Experts
Connect with LNP innovators and engage in the hottest conversations propelling safe, selective and specific extrahepatic delivery. During the dedicated networking sessions, make critical connections, and build meaningful collaborations.